bioRxiv Science⌕ Search

Biology subjects

DeMartino, A. W.

Publications and source records attributed to DeMartino, A. W..

2 recordsLinked to original sources

Cytochrome b5 reductase 4 efficiently reduces Neuroglobin and Cytoglobin

Cytoglobin and Neuroglobin are heme-containing proteins expressed in most vertebrates, including mammals, with still not completely defined physiological roles. Most of the putative functions of cytoglobin/neuroglobin, such as oxygen binding or nitric oxide dioxygenation, rely on the heme iron being in the ferrous (Fe2+) oxidation state. Therefore, it is very possible that reducing systems are active in the cell to maintain both proteins in the ferrous state. We have previously shown that the cytochrome b5 reductase isoform 3/ cytochrome b5 system, the canonical reductase of hemoglobin and myoglobin, can reduce cytoglobin at very fast rates, consistent with a possible physiological role. However this reducing system is unable to reduce neuroglobin, which to date lacks a validated, physiologically feasible reducing system. Here we have studied the interaction of cytochrome b5 reductase isoform 4 with cytoglobin and neuroglobin and found that cytochrome b5 reductase 4 can reduce cytoglobin at rates comparable to those observed with cytochrome b5 reductase 3/ cytochrome b5. Remarkably, it can also reduce neuroglobin efficiently. Studying different surface mutations of cytoglobin and neuroglobin we note that some cytoglobin mutations, in particular R84E and K116E decrease reduction rates by more than 10-fold, whereas surface mutations in neuroglobin that were shown to impair the interaction of neuroglobin with cytochrome c (E60K/D73K/E87K) show little effect on the reduction rates. We conclude that cytochrome b5 reductase 4 can supplement cytochrome b5 reductase 3/ cytochrome b5 roles for cytoglobin reduction in vivo and is a strong candidate for a physiological role as neuroglobin reductase.

biochemistry↗

Engineering a highly selective, hemoprotein-based scavenger as a carbon monoxide poisoning antidote with no hypertensive effect

Carbon monoxide (CO) poisoning causes 50,000-100,000 emergency department visits and [~]1,500 deaths in the United States annually. Current treatments are limited to supplemental and/or hyperbaric oxygen to accelerate CO elimination. Even with oxygen therapy, nearly half of CO poisoning survivors suffer long-term cardiac and neurocognitive deficits related to slow CO clearance, highlighting a need for point of care antidotal therapies. Given the natural interaction between CO and ferrous heme, we hypothesized that the hemoprotein RcoM, a transcriptional regulator of microbial CO metabolism, would make an ideal platform for CO-selective scavenging from endogenous hemoproteins. We engineered an RcoM truncate (RcoM-HBD-CCC) that exhibits high CO affinity (Ka,CO = 2.8x1010 M-1), remarkable selectivity for CO over oxygen (Ka,O2 = 1.4x105 M-1; Ka,CO/Ka,O2 = 1.9x105), thermal stability (Tm = 72{degrees}C), slow autoxidation rate (kox = 1.1 h-1). In a murine model of acute CO poisoning, infused RcoM-HBD-CCC accelerated CO clearance from hemoglobin in red blood cells and was rapidly excreted in urine. Moreover, infused RcoM-HBD-CCC elicited minimal hypertension in mice compared to infused hemoglobin, attributed to a comparatively limited reactivity toward nitric oxide (NO) via dioxygenation (kNOD(RcoM) = 6-8x106 M-1s-1 vs kNOD(Hb) = 6-8x107 M-1s-1). These data suggest that RcoM-HBD-CCC is a safe, selective, and efficacious CO scavenger. Additionally, by limiting hypertension RcoM-HBD-CCC improves end-organ adverse effects compared with hemoglobin-based therapeutics.

biochemistry↗